Cannabix Technologies Inc.

Cannabix Technologies Inc. is a technology company based in Burnaby, British Columbia, Canada, specializing in the development of marijuana and alcohol breath testing technologies. Its core mission is to provide advanced tools for law enforcement, workplaces, and laboratories to accurately detect recent cannabis and alcohol use.

The company's key products include the Cannabix Marijuana Breath Test (MBT) and the BreathLogix Alcohol Breathalyzer. The MBT system utilizes a handheld Breath Collection Unit (BCU) and Breath Cartridge (BC) to collect breath samples for the detection of delta-9 THC, the psychoactive component of marijuana, with samples subsequently analyzed in a laboratory using mass spectrometry. The BreathLogix series offers autonomous and contactless alcohol screening devices primarily designed for workplace settings.

In March 2026, Cannabix Technologies announced the commercial phased rollout of its Marijuana Breath Test (MBT) system, with initial deliveries to industrial and construction clients. This followed a peer-reviewed publication in the Journal of Analytical Toxicology in early March 2026, which confirmed the MBT system's ability to detect delta-9 THC. Led by CEO Rav Mlait, the company maintains a strategic partnership with Omega Laboratories Inc. for the commercialization and laboratory analysis aspects of its MBT technology, positioning itself at the forefront of breathalyzer solutions for evolving cannabis and alcohol detection needs.